San Francisco, CA (PRWEB) June 13, 2011
Questcor Pharmaceuticals (NASDAQ: QCOR) won a 2011 Silver Anvil for the company’s investor relations campaign executed by EVC Group, Inc. Symbolizing the forging of public opinion, the Silver Anvil is the public relations professions’ highest honor. Conferred annually by the Public Relations Society of America, the Silver Anvil acknowledges the highest level of achievement and is the established icon of the “best of the best” public relations practices.
The winning program for Questcor resulted in dozens of new institutional shareholders, expanded sell-side analyst and financial media coverage, as well as multiple invitations to leading healthcare investor conferences. Don M. Bailey, Questcor’s President and Chief Executive Officer, accepted the award at the 2011 Silver Anvil Award Ceremony on June 9, 2011 in New York City.
“Questcor is an extremely well run company that has generated superior returns for its shareholders in the past 18 months,” said Doug Sherk, Founder and CEO of EVC Group. “It has been our privilege to develop and execute this award-winning program with Questcor. Questcor and EVC Group are honored by PRSA’s recognition, which we believe validates a relationship approach to investor relations and a management team that believes in open and clear communication with its shareholders.”
About EVC Group, Inc.
For more information about EVC Group, please visit http://www.evcgroup.com/EnhancingValuation. Follow EVC Group at http://www.twitter.com/evcgroup and http://www.linkedin.com/company/evc-group-inc.
EVC Group is an investor relations and public relations firm that provides advice and execution to businesses of all sizes that need to communicate their unique value to investors, customers and the consumer. EVC Group's practice areas include medical technology, biopharmaceuticals, life sciences, financial & business services, natural resources, and enterprise technology. Established in 2002, EVC Group is well regarded for its strategic thinking; seasoned, senior-level staff; frank counsel; deep relationships and tangible results - results that have a measurable impact on its clients’ businesses. The firm has offices in New York, San Francisco and southern California.
For more information about Quesctor, please visit http://www.questcor.com.
Questcor Pharmaceuticals, Inc. is a biopharmaceutical company whose primary product helps patients with serious, difficult-to-treat medical conditions. Questcor's primary product is H.P. Acthar® Gel (repository corticotropin injection), an injectable drug that is approved by the FDA for the treatment of 19 indications. Of these 19 indications, Questcor currently generates substantially all of its net sales from three indications: the treatment of acute exacerbations of multiple sclerosis in adults, the treatment of nephrotic syndrome, and the treatment of infantile spasms in children under two years of age. With respect to nephrotic syndrome, the FDA has approved Acthar to "induce a diuresis or a remission of proteinuria in the nephrotic syndrome without uremia of the idiopathic type or that due to lupus erythematosus." Questcor is also exploring the possibility of developing markets for other on-label indications and the possibility of pursuing FDA approval of additional indications not currently on the Acthar label where there is high unmet medical need. Questcor also markets Doral(R) (quazepam), which is indicated for the treatment of insomnia characterized by difficulty in falling asleep, frequent nocturnal awakenings, and/or early morning awakenings.